Intrexon Laboratories

The requested name "Intrexon Laboratories" appears to refer to the former Intrexon organization, which is now Precigen, a U.S.-listed biotechnology company focused on gene and cell therapies. Intrexon changed its corporate name to Precigen in February 2020 as it narrowed its strategy to healthcare and precision medicines. Precigen is now a commercial-stage biopharmaceutical company headquartered in Germantown, Maryland, with approved PAPZIMEOS for recurrent respiratory papillomatosis in the U.S. and a broader pipeline spanning immuno-oncology, autoimmune disease, and infectious disease. Its core capabilities center on proprietary therapeutic and platform technologies including AdenoVerse and UltraCAR-T, which support development of targeted gene- and cell-based medicines. Historically, Intrexon also operated non-health businesses, but those assets were divested as part of the transition to Precigen.